Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.66 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | AHR | P35869 | 4/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091314 | 0.85 | NPC1 (0.62) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL4656311 | 0.83 | AHR (0.50) | IMPDH2IMPDH1AHRCYP2A6GPR84 | |
| SCHEMBL97207 | 0.79 | IMPDH2 (0.66) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL6445127 | 0.79 | IMPDH2 (0.66) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL91366 | 0.79 | IMPDH2 (1.00) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL30389000 | 0.79 | IMPDH2 (1.00) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| Hydrochloric Acid SCHEMBL27803164 | 0.78 | IMPDH2 (0.96) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL28194905 | 0.78 | IMPDH2 (0.96) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL30906894 | 0.76 | GFER (0.56) | IMPDH2IMPDH1GFERAHRNR4A2 | |
| SCHEMBL30906895 | 0.76 | GFER (0.56) | IMPDH2IMPDH1GFERAHRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | claimed |
| WO-2024253016-A1 | CHLORIDE ION SENSOR, AND DEVICE FOR DETECTING CANCER CELLS AND/OR EVALUATING DEGREE OF MALIGNANCY OF CANCER CELLS BY USING SAME | 国立研究開発法人産業技術総合研究所 | 2024-12-12 | — | — | WO | claimed |
| CN-118085268-A | Preparation method of amphiphilic molecule with aggregation-induced fluorescence color-changing characteristic | 西北工业大学 | 2024-05-28 | — | — | CN | claimed |
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | disclosed |
| US-12319946-B2 | Methods for producing modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4549431-A1 | COMPOUND FUNCTIONING AS SMARCA2/4 INHIBITOR AND USE THEREOF | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-119490487-A | Polysubstituted tetrahydrocarbazole compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-02-21 | — | — | CN | disclosed |
| CN-119384414-A | Compound used as SMARCA2/4 inhibitor and application thereof | 甘李药业股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2024253016-A1 | CHLORIDE ION SENSOR, AND DEVICE FOR DETECTING CANCER CELLS AND/OR EVALUATING DEGREE OF MALIGNANCY OF CANCER CELLS BY USING SAME | 国立研究開発法人産業技術総合研究所 | 2024-12-12 | — | — | WO | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| CN-1751025-B | Diamine derivatives | DAIICHI SEIYAKU CO | 2010-05-12 | — | — | CN | disclosed |
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | ANIONA APS (DK) | 2009-04-16 | — | — | US | disclosed |
| CN-101263110-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD (JP) | 2008-09-10 | — | — | CN | disclosed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | disclosed |
| EP-1863819-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006087306-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | CHRNA6, CHRNA10, CHRNA2 | IMPDH2 3490/4885IMPDH1 3294/4885GFER 1880/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | IMPDH2 1378/4885IMPDH1 1332/4885GFER 4317/4885 |
| US-20090099153-A1 | NOVEL 8,10-DIAZA-BICYCLO[4.3.1]DECANE DERIVATIVES AND THEIR MEDICAL USE | CHRNA10, CHRNA7, CHRNA3 | IMPDH2 4208/4885IMPDH1 4092/4885GFER 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.